The Gene Therapy Spree Rolls on With $3 Billion Astellas Deal

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Good afternoon, readers. Biogen paid $800 million for Nightstar Therapeutics. Drug giant Roche wants to pony up $4.3 billion deal for Spark Therapeutics in a deal that’s now
Complete Reading

This is the web version of Brainstorm Health Daily, Fortune’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here. Happy Monday, readers! There’s a battle—or, at the very least, a whole lot of investor speculation—brewing in the heart drug space. (Granted, rampant speculation and rumor-mill-churning isn’t exactly
Complete Reading

Hello and happy Monday, readers. Fortune sat down with Brad Loncar, a biotech investor who specializes in cancer immunotherapy, at our offices last week. Loncar runs both a U.S.-based index fund for cancer drug companies and, more recently, launched another one focused on China. It was a fascinating conversation that covered everything from the U.S.
Complete Reading

Ken Griffin, the billionaire founder and CEO of investment firm Citadel, is teaming up with the Michael J. Fox Foundation (MJFF) to fund a new $10 million Parkinson’s research program, Fortune has learned. The program will be structured as a competition dubbed the Ken Griffin Alpha-synuclein Imaging Competition and will largely be funded by an
Complete Reading

Happy Friday, readers! The Food and Drug Administration (FDA) isn’t resting on its laurels in the dog days of summer. In the past week, the FDA has approved five novel new drugs to treat a slew of conditions from cancer to the skin disease psoriasis to tuberculosis (TB) to the sleep disorder narcolepsy. Two of
Complete Reading

Hello and happy Friday, readers! As promised, we have a special guest post up today on Fortune.com – from IDEA Pharma CEO Mike Rea and co-author Eneida Pollozi. This fascinating piece tackles some of the most pressing issues in drug industry and, specifically, in an area that’s dogged some pharma companies for a while now: Namely,
Complete Reading

Happy Friday, readers! Johnson & Johnson doesn’t just want to treat HIV—it wants to prevent against it altogether with an experimental vaccine. The U.S. drug giant announced Friday that will test out the vaccine in the U.S. and Europe this year, according to CNBC. If it proves successful—following testing on thousands of men who have
Complete Reading

The world of stem cell-based medicine has had its fair share of disappointments and regulatory recriminations over wildly inflated claims. But Athersys CEO Gil Van Bokkelen says the stem cell field isn’t getting a fair shake. “It’s a misconception to say stem cells haven’t really delivered,” he tells Fortune in an interview. “This is a
Complete Reading

Create Account



Log In Your Account